Lobaplatin

Drug Profile

Lobaplatin

Alternative Names: D 19466

Latest Information Update: 13 May 2011

Price : $50

At a glance

  • Originator Zentaris
  • Class Antineoplastics; Cyclobutanes; Platinum complexes; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Breast cancer; Chronic myeloid leukaemia; Small cell lung cancer
  • Discontinued Cancer

Most Recent Events

  • 13 May 2011 No development reported - Phase-II for Small cell lung cancer in Canada (IV)
  • 13 May 2011 No development reported - Phase-II for Chronic myeloid leukaemia in Canada (IV)
  • 13 May 2011 No development reported - Phase-II for Breast cancer in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top